Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $32.71

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $32.7143.

AVTX has been the subject of several analyst reports. TD Cowen initiated coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating for the company. Cowen started coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating for the company. BTIG Research reissued a “buy” rating and set a $40.00 price target on shares of Avalo Therapeutics in a research note on Monday, September 29th. Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Tuesday, October 14th.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently bought and sold shares of the stock. BIT Capital GmbH acquired a new position in Avalo Therapeutics during the third quarter worth approximately $25,000. Quadrature Capital Ltd purchased a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at $55,000. Boothbay Fund Management LLC purchased a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at $56,000. ADAR1 Capital Management LLC acquired a new stake in shares of Avalo Therapeutics during the 1st quarter worth $80,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Avalo Therapeutics in the 3rd quarter worth $143,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Stock Performance

AVTX stock opened at $18.56 on Thursday. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The stock’s 50 day moving average price is $17.67 and its 200 day moving average price is $12.00. The firm has a market cap of $336.49 million, a P/E ratio of -3.46 and a beta of 0.84.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.52). On average, research analysts predict that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.